Suggested remit: To appraise the clinical and cost effectiveness of dabigatran etexilate within its marketing authorisation for the secondary prevention of stroke in people who have had an embolic stroke of undetermined source.
Status Awaiting development
Decision None selected
Process TA
ID number 1417

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
26 November 2018 The National Institute for Health and Care Excellence (NICE) has been invited to consider and appraisal of dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source ID 1417. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets dabigatran etexilate has advised that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information the Institute will not be progressing with the scoping exercise. If you have any comments or concerns please contact the project manager for this appraisal via email at

For further information on our processes and methods, please see our CHTE processes and methods manual